679 related articles for article (PubMed ID: 24688145)
1. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Li WX; Gou JF; Tian JH; Yan X; Yang L
Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide analogues for type 2 diabetes mellitus.
Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
[TBL] [Abstract][Full Text] [Related]
4. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.
Deng R; Mei K; Song T; Huang J; Wu Y; Yu P; Yan Z; Liu X
Front Endocrinol (Lausanne); 2024; 15():1289643. PubMed ID: 38348420
[TBL] [Abstract][Full Text] [Related]
8. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Li Z; Zhang Y; Quan X; Yang Z; Zeng X; Ji L; Sun F; Zhan S
PLoS One; 2016; 11(5):e0154206. PubMed ID: 27158818
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.
Berlie H; Hurren KM; Pinelli NR
Diabetes Metab Syndr Obes; 2012; 5():165-74. PubMed ID: 22826635
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.
Liu FP; Dong JJ; Yang Q; Xue XZ; Ren ZF; Gan YZ; Liao L
J Diabetes; 2015 May; 7(3):322-8. PubMed ID: 25047138
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
Shyangdan DS; Royle PL; Clar C; Sharma P; Waugh NR
BMC Endocr Disord; 2010 Dec; 10():20. PubMed ID: 21143938
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Banerjee M; Pal R; Mukhopadhyay S; Nair K
J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.
Krisanapan P; Sanpawithayakul K; Pattharanitima P; Thongprayoon C; Miao J; Mao MA; Suppadungsuk S; Tangpanithandee S; Craici IM; Cheungpasitporn W
Diseases; 2024 Jan; 12(1):. PubMed ID: 38248365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
